Retrasib will issue 50 million new shares with a face value of RON0.1. The shares will be allocated to stockholders free of charge, the company said.
Brothers Octavian and Calin Buzoianu control 80.2% in Retrasib.
The company reported a net profit of RON0.95 million in the first half, down from RON2.51 million in the same period of 2010.
On the Bucharest bourse August 25, Retrasib closed down 2.75% at RON0.5135 a share. (EUR1=RON4.2402)